Keywords: UK, NICE, Novartis, Xolair, GlaxoSmithKline, Arzerra, Pfizer, Torisel, Amgen, Prolia, Napo, Treanda

Negative decisions from UK’s NICE for Novartis’ Xolair, GSK’s Arzerra and Pfizer’s Torisel, but OK for Amgen’s Prolia

Article | 27 October 2010

Print This

The UK drugs watchdog body the National Institute for Health and Clinical Excellence (NICE) said this morning that it is ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in